AU2013305884B2 - Antibodies to risperidone haptens and use thereof - Google Patents

Antibodies to risperidone haptens and use thereof Download PDF

Info

Publication number
AU2013305884B2
AU2013305884B2 AU2013305884A AU2013305884A AU2013305884B2 AU 2013305884 B2 AU2013305884 B2 AU 2013305884B2 AU 2013305884 A AU2013305884 A AU 2013305884A AU 2013305884 A AU2013305884 A AU 2013305884A AU 2013305884 B2 AU2013305884 B2 AU 2013305884B2
Authority
AU
Australia
Prior art keywords
risperidone
antibody
group
sample
labeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013305884A
Other languages
English (en)
Other versions
AU2013305884A1 (en
Inventor
Linda COLT
Thomas R. DECORY
Pieter Rik HASPESLAGH
Eric Hryhorenko
Banumathi Sankaran
Theresa TUBBS
Maarten VLIEGEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saladax Biomedical Inc
Original Assignee
Saladax Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saladax Biomedical Inc filed Critical Saladax Biomedical Inc
Publication of AU2013305884A1 publication Critical patent/AU2013305884A1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV Request for Assignment Assignors: JANSSEN PHARMACEUTICA NV, ORTHO-CLINICAL DIAGNOSTICS, INC
Application granted granted Critical
Publication of AU2013305884B2 publication Critical patent/AU2013305884B2/en
Priority to AU2018200107A priority Critical patent/AU2018200107B2/en
Priority to AU2019284059A priority patent/AU2019284059B2/en
Assigned to SALADAX BIOMEDICAL INC. reassignment SALADAX BIOMEDICAL INC. Request for Assignment Assignors: JANSSEN PHARMACEUTICA NV
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013305884A 2012-08-21 2013-08-20 Antibodies to risperidone haptens and use thereof Active AU2013305884B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018200107A AU2018200107B2 (en) 2012-08-21 2018-01-05 Antibodies to risperidone haptens and use thereof
AU2019284059A AU2019284059B2 (en) 2012-08-21 2019-12-23 Antibodies to risperidone haptens and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691615P 2012-08-21 2012-08-21
US61/691,615 2012-08-21
PCT/US2013/055794 WO2014031645A1 (en) 2012-08-21 2013-08-20 Antibodies to risperidone haptens and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200107A Division AU2018200107B2 (en) 2012-08-21 2018-01-05 Antibodies to risperidone haptens and use thereof

Publications (2)

Publication Number Publication Date
AU2013305884A1 AU2013305884A1 (en) 2015-03-05
AU2013305884B2 true AU2013305884B2 (en) 2017-10-05

Family

ID=50148308

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013305884A Active AU2013305884B2 (en) 2012-08-21 2013-08-20 Antibodies to risperidone haptens and use thereof
AU2018200107A Active AU2018200107B2 (en) 2012-08-21 2018-01-05 Antibodies to risperidone haptens and use thereof
AU2019284059A Active AU2019284059B2 (en) 2012-08-21 2019-12-23 Antibodies to risperidone haptens and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018200107A Active AU2018200107B2 (en) 2012-08-21 2018-01-05 Antibodies to risperidone haptens and use thereof
AU2019284059A Active AU2019284059B2 (en) 2012-08-21 2019-12-23 Antibodies to risperidone haptens and use thereof

Country Status (10)

Country Link
US (3) US9751953B2 (https=)
EP (1) EP2888284B1 (https=)
JP (3) JP6374387B2 (https=)
CN (2) CN104736565B (https=)
AU (3) AU2013305884B2 (https=)
CA (1) CA2882563C (https=)
ES (1) ES2926662T3 (https=)
PL (1) PL2888284T3 (https=)
PT (1) PT2888284T (https=)
WO (1) WO2014031645A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
EP3462173B1 (en) * 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
CN104736565B (zh) * 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
JP6523020B2 (ja) * 2015-03-31 2019-05-29 古河電気工業株式会社 生体分子の検出又は定量方法、及び生体分子の検出又は定量用標識試薬粒子
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
WO2020160199A1 (en) * 2019-01-31 2020-08-06 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
CN110938072A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种利培酮人工抗原及其制备方法
CN111808046B (zh) * 2020-06-30 2022-11-11 杭州同舟生物技术有限公司 一种喹硫平人工半抗原、人工抗原及其制备方法和应用
CN112608310B (zh) * 2020-12-17 2022-03-29 北京丹大生物技术有限公司 一种利培酮和9-羟基利培酮半抗原、抗原和抗体以及其应用
CN114685470B (zh) * 2020-12-25 2023-08-18 长沙博源医疗科技有限公司 一种利培酮关键基团衍生物、免疫原、抗利培酮特异性抗体及其制备方法与应用
CN116003404B (zh) * 2022-12-14 2024-10-01 杭州同舟生物技术有限公司 一种利培酮人工半抗原、人工抗原及其制备方法和应用
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115733A1 (en) * 2010-03-16 2011-09-22 Saladax Biomedical Inc. Risperidone immunoassay

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022780A (en) 1973-03-06 1977-05-10 Imperial Chemical Industries Limited Process for the manufacture of indole derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
CA2064194A1 (en) * 1989-07-27 1991-01-28 Nelson Teng Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
DE69232002T2 (de) 1991-06-07 2002-06-06 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays unter Verwendung von markierten Hapten-Analogen
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5616505A (en) 1992-03-27 1997-04-01 Abbott Laboratories Haptens tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
DK0582368T3 (da) 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
CA2192467C (en) 1994-06-10 2009-03-31 Alireza Rezaie Calcium binding recombinant antibody against protein c
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
DE60335428D1 (de) 2002-01-31 2011-02-03 Randox Lab Ltd Immunogene, Antikörper und Konjugate für Ketamin und dessen Metaboliten
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
AU2003217936A1 (en) 2002-03-28 2003-10-13 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
AU2003259256A1 (en) 2002-07-29 2004-02-16 Potomac Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
US7977072B2 (en) * 2002-11-20 2011-07-12 B.R.A.H.M.S Gmbh Sandwich immunoassay for identifying partial proANP peptides
US20040193446A1 (en) 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
BRPI0413595B8 (pt) 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
ES2335589T3 (es) 2003-09-23 2010-03-30 Fermion Oy Preparacion de quetiapina.
CN101921279A (zh) 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
DE602004024236D1 (en) 2003-12-12 2009-12-31 Inverness Medical Switzerland Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
US7087699B2 (en) 2004-05-17 2006-08-08 Acushnet Company Sulfur-containing composition for golf equipment, and method of using same
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060177883A1 (en) * 2005-02-08 2006-08-10 Saladax Biomedical Inc. 5-Fluoro-uracil immunoassay
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
JP5026761B2 (ja) * 2006-10-06 2012-09-19 公立大学法人大阪府立大学 ハプテン化合物および抗体
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
JP2010507648A (ja) 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
WO2008087557A2 (en) 2007-01-08 2008-07-24 Actavis Group Ptc Ehf An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
CN101245065B (zh) 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
RU2010116351A (ru) 2007-09-27 2012-05-20 Новартис АГ (CH) Мониторинг лекарственных средств
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
CN102245605B (zh) 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
EP2347015A4 (en) * 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
EP2389169A1 (en) 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
EP2406289B1 (en) 2009-03-10 2017-02-22 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
CN102573913B (zh) 2009-07-31 2014-06-18 阿森迪斯药物股份有限公司 可生物降解的基于聚乙二醇的水不溶性水凝胶
CN102574917A (zh) 2009-08-17 2012-07-11 株式会社未来创药研究所 含有抗hb-egf抗体作为有效成分的药物组合物
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP3476218A1 (en) 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN101987836B (zh) * 2010-08-31 2012-11-07 华南农业大学 氯丙嗪半抗原、人工抗原和抗体及其制备方法和应用
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
SG11201501130PA (en) 2012-08-16 2015-04-29 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
TR201816378T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Olanzapin haptenleri.
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
ES2822907T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de quetiapina para su uso en inmunoensayos
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
ES2904838T3 (es) 2012-08-21 2022-04-06 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN108431040B (zh) * 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115733A1 (en) * 2010-03-16 2011-09-22 Saladax Biomedical Inc. Risperidone immunoassay

Also Published As

Publication number Publication date
AU2019284059B2 (en) 2022-03-10
US20180022827A1 (en) 2018-01-25
CA2882563C (en) 2022-11-29
JP2015532646A (ja) 2015-11-12
CN104736565A (zh) 2015-06-24
EP2888284A1 (en) 2015-07-01
WO2014031645A1 (en) 2014-02-27
JP6374387B2 (ja) 2018-08-15
US20140057301A1 (en) 2014-02-27
US10793644B2 (en) 2020-10-06
AU2013305884A1 (en) 2015-03-05
EP2888284A4 (en) 2016-03-30
PL2888284T3 (pl) 2023-02-27
HK1211957A1 (en) 2016-06-03
US9751953B2 (en) 2017-09-05
AU2018200107B2 (en) 2019-10-03
CA2882563A1 (en) 2014-02-27
AU2018200107A1 (en) 2018-01-25
PT2888284T (pt) 2022-11-18
CN108517014A (zh) 2018-09-11
JP6971927B2 (ja) 2021-11-24
US20200399400A1 (en) 2020-12-24
ES2926662T3 (es) 2022-10-27
AU2019284059A1 (en) 2020-01-23
CN104736565B (zh) 2019-03-12
JP2021003118A (ja) 2021-01-14
JP2019001788A (ja) 2019-01-10
EP2888284B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
AU2013305884B2 (en) Antibodies to risperidone haptens and use thereof
AU2017261585B2 (en) Antibodies to paliperidone haptens and use thereof
AU2013305970B2 (en) Antibodies to aripiprazole haptens and use thereof
AU2013305936B2 (en) Haptens of risperidone and paliperidone
AU2013305904B2 (en) Antibodies to quetiapine haptens and use thereof
HK1211957B (en) Antibodies to risperidone haptens and use thereof
HK40030125A (en) Antibodies to quetiapine haptens and use thereof
HK40002082B (en) Haptens of risperidone and paliperidone
HK40002082A (en) Haptens of risperidone and paliperidone

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JANSSEN PHARMACEUTICA NV

Free format text: FORMER APPLICANT(S): JANSSEN PHARMACEUTICA NV; ORTHO-CLINICAL DIAGNOSTICS, INC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SALADAX BIOMEDICAL INC.

Free format text: FORMER OWNER(S): JANSSEN PHARMACEUTICA NV